Back to top

Ascendis Pharma reports Q2 EPS 90c, consensus 77c

Reports Q2 revenue $339.29M, consensus $329.9M. “Our patient focus has driven achievement of important milestones and strong demand for our TransCo...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ascendis Pharma A/S (ASND)